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Background: The use of a laryngeal mask airway (LMA) in appropriate patients supports fast-track anesthesia with a
lower incidence of postoperative airway-connected adverse events. Data on the most favorable anesthetic in this
context, with the lowest rate of upper airway complications and fast emergence times, are controversial and
limited. Desflurane seems to match these criteria best, but large randomized controlled trials (RCTs) with a
standardized study protocol are lacking. Therefore, we aim to compare desflurane with other commonly used
anesthetics, sevoflurane and propofol, in a sufficiently powered RCT. We hypothesize that desflurane is noninferior
regarding the frequency of upper airway events and superior regarding the emergence times to sevoflurane and
propofol.
Methods/Design: A total of 351 patients undergoing surgery with an LMA will be included in this prospective,
randomized, double-blind controlled, multicenter clinical trial. The patients will be randomly assigned to the three
treatment arms: desflurane (n = 117), sevoflurane (n = 117), and propofol (n = 117). The emergence time (time to
state the date of birth) will be the primary endpoint of this study. The secondary endpoints include further
emergence times, such as time to open eyes, to remove LMA, to respond to command and to state name.
Additionally, we will determine the frequency of cough and laryngospasm, measured intraoperatively and at
emergence. We will assess the postoperative recovery on the first postoperative day via the Postoperative Quality
Recovery Scale.
Discussion: Despite increasing importance of cost-effective and safe anesthesia application, we lack proof for the
most advantageous anesthetic agent, when an LMA is used. There are only a few RCTs comparing desflurane to
other commonly used anesthetics (sevoflurane, propofol and isoflurane) in patients with LMA. These RCTs were
conducted with small sample sizes, huge interstudy variability, and some also showed strong biases. The present
multicenter RCT will provide results from a large sample size with a standardized study protocol and minimized
bias, which is feasible in the clinical routine. Furthermore, we will expand our knowledge regarding the most
favorable recovery on the first postoperative day, which impacts patients’ comfort after surgery.
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Background and rationale
Fundamental pillars of anesthesia care are the safe and
measured application of anesthesia. Improvement of fa-
cility and resource utilization with a high patient turn-
over and early discharge of patients from the operating
room and hospital is becoming increasingly important.
This hinges on a rapid emergence and early recovery from
anesthesia. Desflurane’s low blood gas coefficient supports
general anesthesia (GA) in a fast-track technique, even in
obese patients [1]. The use of a laryngeal mask airway
(LMA) attenuates the risk of postoperative airway-
connected complications in comparison to endotracheal
tubes (ETT) in GA [2].
Desflurane’s possible airway irritant properties com-
pared to other anesthetics like sevoflurane, propofol and
isoflurane are still the subject of discussions [1]. How-
ever, studies comparing the risk of intraoperative upper
airway adverse events like cough and laryngospasm (LS)
vis-à-vis other common anesthetics are limited. One
meta-analysis [3] considered these adverse events in pa-
tients with LMA and could not evince a greater incidence
with desflurane compared only to sevoflurane anesthesia.
Data regarding recovery times were not assessed in this
meta-analysis. Therefore, we have recently performed a
further meta-analysis [4] comparing desflurane’s proper-
ties to other commonly used anesthetics with LMA: iso-
flurane, sevoflurane and propofol. We identified only 13
randomized controlled trials that have analyzed the vari-
ables of upper airway adverse events (intraoperative cough
(CO), cough at emergence (CE) and laryngospasm (LS))
and the recovery times (time to open eyes (TOE), to re-
move LMA (TLR), to respond to command (TRC) and
time to state date of birth (TSB)). While the frequency
of upper airway adverse events did not differ between
the analyzed anesthetics, the recovery times in the des-
flurane groups were superior to the other anesthetic
groups. The variable CO showed a non-significant RR
(95 % CI) of 1.12 (0.63, 2.02), (P = 0.70), between desflur-
ane (n = 284) and all other examined anesthetic agents
(n = 313). CE was only examined after desflurane (n =
148) and sevoflurane (n = 146) administration and also
indicated no difference, RR [95 % CI] of 1.49 (0.55, 4.02),
(P = 0.43). LS was rare and desflurane (n = 262) showed
no difference when compared to all other analyzed an-
esthetics (n = 289), or when compared only to sevoflur-
ane, RR (95 % CI) of 1.03 (0.33, 3.20), (P = 0.96). All
emergence-time variables were significantly faster in the
desflurane group. Due to the small sample sizes, huge
study protocol distinctions and the fact that the examined
variables were mainly secondary endpoints of the included
studies, these findings have to be seen within their limits.
Additional large randomized controlled trials are indicated
to validate the results of our meta-analysis [5].Objectives and study design
This will be a multicenter, controlled, double-blind, ran-
domized, three-arm parallel, interventional clinical study.
The purpose of this study will be to assess the following:
1) If desflurane is superior in achieving a faster
emergence from anesthesia (when patient can state
his/her date of birth).
2) If desflurane is noninferior in the occurrence of
upper airway complications compared to sevoflurane
or total intravenous anesthesia with propofol in the
setting of laryngeal mask airway.
Specific primary objective
The specific primary objective is to determine the time
of emergence from anesthesia with LMA (defined as time
between cessation of anesthesia until patient is able to
state his/her date of birth (TSB) on command) after
desflurane compared to sevoflurane or propofol.
Specific secondary objectives
The specific secondary objectives are to determine the
frequency of airway reactions (CO, LS, laryngospasm at
emergence (LSE) and CE) in patients undergoing desflur-
ane anesthesia with LMA, compared to sevoflurane or
propofol. Additionally, we will analyze further emergence
times (TLR, TOE, TRC, time to state the full name (TSN)
on command and the recovery index [6]) in the same pa-
tients after cessation of anesthesia.
Other secondary objectives
Other secondary objectives are to determine the influence
of gender on the patients’ reactions, the anesthesia safety
variables including hemodynamic stability, the frequency
and quantity of postoperative nausea, vomiting and pain,
the discharge times, the pharmacoeconomics and the re-
covery on the first postoperative day (1st POD).
Methods/Design
Study setting
This multicenter study will be conducted in four German
study centers (University hospitals of Aachen and Ulm
and the regional hospitals of Reutlingen and Halle).
Eligibility criteria
Investigators in each center will be selected and super-
vised by the local coordinating principal investigator. To
ensure the blinding process, at least two investigators
will be needed, when a patient is enrolled in this study.
Therefore the screening and enrollment process will be
performed according to the logistical possibilities of each
center. All potential patients meeting the inclusion cri-
teria will be documented in a screening log kept at each
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have to be stated in the screening log.
Inclusion criteria: A written informed consent prior to
study participation will be mandatory. Participants in the
study have to be adult patients between 18 and 75 years
of age. They have to be scheduled to undergo elective
surgery with a planned duration of 0.5 to 2 hours and
the use of LMA. Both sexes will be included, and further
inclusion criteria are an American Society of Anesthesi-
ologists (ASA) physical status 1 to 3 and body mass
index (BMI) <35 kg m−2.
Exclusion criteria: Subjects fulfilling one or more of
the following exclusion criteria will not be included in
the study: patients with planned additional regional and
local anesthesia, with asthma or chronic obstructive pul-
monary disease (COPD) grade IV, contraindication for
the use of a LMA, known allergy or hypersensitivity to
any drugs administered during this study. Furthermore,
women who are pregnant, breast-feeding or of childbear-
ing potential and not using adequate contraceptive
methods will be excluded. Patients legally unable to give
written informed consent, nonfluency in German lan-
guage, with severe psychiatric or neuropsychiatric disor-
ders or recent (<6 months) history of alcohol or drug
abuse will not be included. The participation in a drug or
device trial within the previous 30 days will be a further
exclusion criterion.
General interventions for all patients
Premedication: All patients will receive an oral adminis-
tration of up to 7.5 mg midazolam 30 to 45 minutes pre-
operatively, according to the clinical routine of each
center.
Induction: Upon arrival into the surgery room, a stand-
ard monitoring will be applied to all patients. This will
consist of continuous electrocardiogram (ECG), measure-
ment of non-invasive blood pressure (NIBP) and periph-
eral oxygen saturation (SpO2). A connection of Bispectral
Index (BIS) monitoring will follow. After pre-oxygenation
with oxygen (FiO2 = 1.0) for 3 minutes via face-mask, all
patients will receive remifentanil injection via infusion
pump at an initial rate of 0.5 μg kg−1 over 60 seconds and
1.5 to 2.5 mg kg−1 (plus 2 ml lidocaine 1 %) propofol by
bolus titration intravenous (i.v.). After loss of conscious-
ness, the LMA will be inserted and blocked with a cuff
pressure at 30 cm H2O. Teeth marks on the device will
help to check the correct insertion. The leakage will have
to be controlled by applying a positive airway pressure
of 25 cm H2O. A reassessment will take place after
5 minutes. If the LMA is not tight, a replacement of
LMA will follow. After a second failure of LMA place-
ment, an alternative airway will be applied.
Maintenance: All patients will receive a postoperative
nausea and vomiting (PONV) prophylaxis with 8 mgdexamethasone and 4 mg ondansetron, if the Apfel-
Score is ≥2. Analgesia will be maintained with remifentanil
injection via infusion pump at a rate of 0.15 μg kg−1 min−1.
Dosage will be adapted according to clinical needs based
on the patient’s hemodynamic (difference of NIBP and HR
greater than 20 % from baseline), autonomic (sweating,
salivation, or flushing) and somatic (movement or swallow-
ing) signs. Twenty minutes before the estimated end of
surgery, all patients will receive 0.05 to 0.1 mg kg−1 piritra-
mide and 15 mg kg−1 metamizole i.v. The inspired oxygen
concentration will be adjusted to 35 to 50 %, or above this
range if medically indicated. The end-expiratory CO2 level
during the maintenance of anesthesia should be kept be-
tween 36 and 45 mmHg. The use of muscle relaxants is
undesired, except for emergency situations. Spontaneous
breathing or controlled ventilation with LMA will be ap-
plied during maintenance of anesthesia, according to the
standard operating procedure of each participating center.
Inspired desflurane concentrations of >8 vol. % and sevo-
flurane >2.2 vol. % have to be avoided. The systolic blood
pressure should be kept at ≥90 mmHg (or ≥65 mmHg
for mean arterial blood pressure), and a relative vari-
ation > 20 % from baseline values has to be avoided and
requires appropriate treatment. If indicated additional
bolus injection of propofol is permissible in patients.
End of anesthesia: At five minutes before planned ter-
mination of surgery, remifentanil will be discontinued.
The LMA will be removed when the upper airway reflexes
are fully recovered and the respiratory function is ad-
equate (regular spontaneous breathing with a frequency of
at least eight breaths per minute and SaO2 >95 %) and
when the patient opens his/her eyes on request or is
able to follow any other requests. In addition, the pa-
tient has to be hemodynamically stable before removal
of LMA. The patients will be admitted to the Post
Anesthesia Care Unit (PACU) following surgery. They
will receive 0.05 mg kg−1 piritramide if the visual ana-
log scale (VAS) for pain is more than 30.Specific interventions
There will be three parallel intervention groups receiving
different anesthetics for the maintenance of anesthesia
after the induction phase and placement of the LMA.
Group 1 will receive desflurane. After setting the fresh
gas flow at 2l min−1, the desflurane vapor will be turned
to 12 vol. % until the desired end-expiratory target con-
centration of 0.8 MAC (minimal alveolar concentration)
or 4 to 5 vol. % desflurane is achieved. Thereafter, a re-
duction of the fresh gas flow to 500 to 1,000 ml will be
performed to maintain anesthesia. Desflurane concentra-
tion will be adjusted to maintain a BIS index value between
40 and 60. Five minutes before estimated termination of
surgery, the vapor will be set to zero. At the end of the
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point will be defined as time zero (T0).
Group 2 will receive sevoflurane. After setting the
fresh gas flow at 2l min−1, the sevoflurane vapor will be
turned to 8 vol. % until the desired end-expiratory target
concentration of 0.8 MAC or 1.2 to 1.4 vol. % sevoflurane
is achieved. Thereafter, a reduction of the fresh gas flow to
500-1000ml will be performed to maintain anesthesia.
Sevoflurane concentration will be adjusted to maintain a
BIS index value between 40 and 60. Five minutes before
estimated termination of surgery, the vapor will be set to
zero. At the end of the surgery maximum fresh gas flow
will be applied. This time-point will be defined as time
zero (T0).
Group 3 will receive propofol via infusion pump at an
initial rate of 5 to 7 mg kg−1 h−1 propofol and then ad-
justed to maintain a BIS index value between 40 and 60.
Five minutes before estimated termination of surgery the
propofol concentration will be halved. Propofol will sub-
sequently be discontinued and maximum fresh gas flow
with FiO2 = 1.0 will be applied at the end of surgery.
This time-point will be defined as time zero (T0).
Interventions - modifications
All drugs used in this trial are anesthetics used daily in
the clinical routine of all participating centers. Harms
are not anticipated in any study treatment. All possible
side effects are described in the summary of medicinal
product characteristics (SmPC). Other potential side ef-
fects and changes in the frequency of possible side ef-
fects are not expected during the trial. A modification or
discontinuation of the assigned study intervention is not
expected. In the event of modifications or discontinuations
of the study treatment, study participants will be retained
in the study to enable data collection and preclude missing
data.
Outcomes
Primary outcome measures
The primary objective of this trial is to investigate,
whether the emergence time until the stating of the date
of birth after desflurane anesthesia is superior to the
time after sevoflurane or propofol anesthesia. The selec-
tion of stating the date of birth as the primary clinical
outcome variable is associated with the result of our lat-
est meta-analysis [4]. This meta-analysis supposes faster
emergence times in the desflurane-treated patients, but the
included studies had only small sample sizes ≤65 patients
per group. Furthermore, they were not all powered for this
outcome variable, and the study protocols were not stan-
dardized for all patients. The time to state the date of birth
was chosen, since this variable requires the most conscious
answer compared to the other emergence variables. This
primary outcome time variable is defined as time betweencessation of anesthesia (T0) until the patient is able to state
his/her date of birth on command (given every 20 sec.)
and will be measured in minutes and seconds.
Secondary outcome measures
The secondary outcome measures will be the deter-
mination of the following additional emergence times:
 Time to remove laryngeal mask (TLR)
 Time to open eyes on command (TOE)
 Time to respond on command to press hand (TRC)
 Time to state the full name on command (TSN)
 Recovery Index RI = 1 + Aldrete5 min/
[(2 x extubation time) + 1 x opening eyes time)] [6]
These secondary outcome variables will also be assessed
in minutes and seconds after cessation of anesthesia (T0).
Furthermore, we aim to analyze the frequency of upper
airway events in desflurane-anesthetized patients com-
pared to sevoflurane and propofol. These variables were
also analyzed in our meta-analysis [4] and indicated
that there were no distinctions between the anes-
thetics. According to the emergence times, the in-
cluded studies had only small sample sizes and were
not all powered for these variables. Our study is also
powered to show a noninferiority of intraoperative
coughs in desflurane versus sevoflurane and propofol
anesthetized patients. The following upper airway events
will be assessed:
 Frequency of intraoperative coughs, CO (induction/
maintenance) - noninferiority design
 Frequency of intraoperative laryngospasm, LS
(induction/maintenance)
 Frequency of cough at emergence, CE
 Frequency of laryngospasm at emergence, LSE
Other outcome measures
Other outcome measures will include the following:
 Sex effects
 Measuring depth of anesthesia (BIS)
 Hemodynamic parameters (NIBP/Heart Rate (HR))
 Requirement of catecholamines
 Respiratory parameters (Airway pressures and end-
tidal carbon dioxide: CO2)
 Modified Aldrete score
 VAS pain in the PACU
 Nausea in the PACU
 Frequency of vomiting in the PACU
 Time to readiness to be discharged from PACU
 Pharmacoeconomics
 Postoperative Quality Recovery Scale (PQRS)
including the recovery on 1st POD
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A participant chart is shown in Additional file 1. Eligible
patients, scheduled for surgery, will be presented to the
anesthesia department for the general anesthesia consent
preoperatively. Additionally, a blinded sub-investigator
will explain the nature and purpose of the study to these
patients and seek a written informed consent for the
study (time point A, before surgery). The same investiga-
tor will collect the following baseline characteristics after
the patient enrollment (time point A):
 Age
 Sex
 Weight
 Height
 BMI
 Smoking status (nonsmoker, current smoker-amount
of pack years, ex-smoker)
 Contraceptives (woman - yes/no)
 Pre-existing diseases and medical/surgical history
 Classification according to the American Society of
Anesthesiologists (ASA)
 Apfel Score
 Baseline (Postoperative Quality Recovery Scale)
PQRS testing prior to surgery (see Additional file 2)
Shortly before surgery on the same day (time point B),
an unblinded investigator will randomize the patients
with sequentially numbered, opaque, sealed envelopes
(SNOSE).
The same unblinded investigator will perform anesthesia
(time point C, surgery) and assess the intraoperative vari-
ables in the respective patient:
 Depth of anesthesia (BIS)
 Standard safety parameters: ECG, SpO2 and end-
tidal CO2, and NIBP
 Ventilation pressure parameters: Ppeak, Pmean, and
PEEP
 Type of performed surgery
 Recording of the end-expiratory applied volatile
anesthetic concentration/applied amount of propofol
for maintenance
 Pharmacoeconomics: Total amount of intraoperative
required catecholamines, of additionally applied
propofol as rescue medication, of wasted propofol at
the end of the surgery in the propofol group and of
intraoperative remifentanil and piritramide
consumption.
 Time points of anesthesia induction, LMA insertion,
administration of the study treatments, anesthesia
and surgery duration
 Frequency of intraoperative (induction/maintenance)
coughs and laryngospasmsThe blinded investigator will enter the operating
room at the time point T0, which starts with cessation
of anesthesia and application of maximum fresh gas
flow and predefines the measurement start-time point
for the time variables. The unblinded investigator
will ensure that the blinded individual is precluded
from recognizing which anesthetic was used, by
masking the ventilator. The blinded investigator will
assess the following postoperative variables during
time point D:
Assessment of airway reactions
 Frequency of CE and LSE
 Emergence times: TSB, TLR, TOE, TRC, TSN
 The modified Aldrete scores with a 10-point scale
will be recorded 5 minutes after removal of LMA
(see Additional file 3)
Time point E starts with admission of the patient to
the PACU. The blinded investigator will assess the fol-
lowing variables:
 The modified Aldrete scores with a 10-point scale
will be recorded every 15 minutes until discharge
from the PACU (see Additional file 3)
 Time-point of readiness to be discharged from the
PACU (Aldrete Score ≥9) (see Additional file 3)
 Assessment PQRS-T40, which is 40 minutes after
the time point T0 (see Additional file 2).
 The VAS pain score will be self-evaluated and
recorded by 100-mm visual analog scale (VAS)
(with 0 corresponding to no pain and 100
corresponding to maximal pain) every 15 minutes
after admission to the PACU. For postoperative
analgesia, the patients will receive 0.05 mg kg−1
piritramide, in order to maintain a VAS pain
score ≤30 mm
Other measurements in the PACU (blinded assessor)
include the following:
 Nausea in the PACU will be evaluated using an
11-point verbal rating scale (VRS) (with 0
corresponding to no nausea and 10 corresponding
to extreme nausea) at admission and discharge
from the PACU and every 15 minutes in the
PACU
 Count of vomiting in the PACU
 Consumption of piritramide in the PACU
Time point E: First post-op day: (telephone interview/
visit at ward):
 PQRS-D1 (see Additional file 2)
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Sample-size estimates for both considerations (superiority
and noninferiority) were calculated separately. All sample
sizes were calculated using a type 1 error, α = 0.05, and
power of 0.80. The primary outcome calculations were
carried out based on a one-way analysis of variance
(same n) with three groups. The variances and means
were estimated for the primary outcome variable time
to state the date of birth from our meta-analysis [4].
For the sevoflurane, propofol and desflurane groups,
means were set to 8.75, 6.8 and 5.6 minutes, respect-
ively. A standard deviation of 3 minutes was consid-
ered (these parameters correspond to an effect size (f )
of 0.43). A sample size of 19 patients per group is
needed to detect such an effect for our superiority
hypothesis.
The sample size for the noninferiority hypothesis
was calculated based on the secondary outcome vari-
able cough overall (CO). Using the normal approxima-
tion to the binomial and assuming a proportion of the
outcome in the population between 0.07 and 0.10 and
noninferiority bound of 0.20 a sample size of 81 and
112, respectively, is required to claim noninferiority.
The margin delta of 20 % was chosen for clinical con-
siderations. We claim that a difference of cough occur-
rence up to 20 % is clinically not relevant. This is
justified by the result of our meta-analysis [4], where
the identified coughs had never lead to a serious im-
pact on the patients’ outcomes.
The sample size calculation for noninferiority of treat-
ment is based on a sample size formula published by Black-
welder [7]. Considering data from the literature, a dropout
rate of 5 patients per group (for example, requirement of
endotracheal intubation, protocol deviations and losses for
first postoperative day- follow up) is expected. We decided
therefore to include 117 patients per group, to cover the
calculated sample size of 19 + 5 patients per group for the
superiority hypothesis as well as 112 + 5 patients for the
noninferiority hypothesis. Altogether, there will be 351
randomized patients.Recruitment
Each participating center will recruit in 5 months as
many patients as possible according to their clinical rou-
tine during the preoperative anesthesia consultation. Be-
fore inclusion of study patients, each center must ensure
that at least two investigators are available: one physician
for the randomization and the intraoperative visit and
the second one for the pre- and postoperative visit. The
exact time point of the informed consent has to be doc-
umented in written form in the patient source data to
enable reproducing the sequence of patient recruitment
and randomization, in order to prevent selection bias.Randomization
The responsible biostatistician will perform a study-
specific computer-generated randomization (study arms,
number of blocks and block lengths) according to the
study-specific biometric specifications, by using the soft-
ware framework “R” [8]. The complete randomization
list and potential block sizes will only be accessible by
the biostatistician of the study. To guarantee adequate
allocation concealment, the group assignments will be
preserved in sequentially numbered, sealed, opaque en-
velopes and these will be provided to the principle inves-
tigator of each center at the beginning of the study by
the biostatistician. The principle investigator will ensure
that only the unblinded investigators have access to these
envelopes and that they will be opened in sequential order
of the patients’ surgery time points. Additionally, he will
have to assure that the anesthesia is truly performed ac-
cording to the assigned intervention, to avoid performance
bias. In order to maintain blinding during enrollment and
data entry to the electronic case report form (eCRF), two
different accounts will be created per center. By utilizing
the first user account, access to intraoperative data, as well
as randomization, will be possible. Using the second ac-
count, entry of pre- and postoperative data will be permit-
ted. Patients in compliance with all inclusion criteria and
none of the exclusion criteria will be randomly assigned
into one of the three study groups: desflurane, or sevoflur-
ane, or total intravenous anesthesia with propofol.
Access to randomization is reserved solely to the intra-
operative investigator and has to be done shortly before
surgery. The time point of envelope opening, the patient
initials and the screening number of the patient will be
written on the appropriate envelope before it is opened.
The envelopes have to be safely stored in the intraopera-
tive patient file. Within a center, the randomization num-
ber will occur in succession. The number will contain
information about the randomizing study site and the pa-
tient sequence. The randomization number will consist of
six digits, the first three for the center and the last three
for the patient, for example, 001 to 001 (for center 001
and the first patient included). This randomization code
will be used to label all information collected for each pa-
tient. The monitors of the study will check carefully that
the envelopes were really used in the correct sequence
and that the signed informed consent occurred definitively
before opening of the randomization envelope.
Blinding
The trial participant and the investigator performing the
pre- and postoperative visits will remain blinded through-
out the entire study period. The unblinded intraoperative
investigator will ensure that the blinded individual is pre-
vented from recognizing which anesthetic was used, by
masking the ventilator with an opaque board before the
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blinded investigator will not have access to the anesthesia
records until the study participation of each patient is
completed.
Unblinding procedures
In the event of medical emergency that requires identifica-
tion of an individual patient’s treatment, blinded investiga-
tors will be allowed to contact the unblinded investigator
or peruse the anesthesia protocols. The reason must be
documented in the patient’s medical record and eCRF and
must explain why revealing the treatment assignment was
essential to guide subsequent intervention and therapy.
Data collection methods
The coordinating principal investigator will ensure local
training to enhance the data collection quality and reduce
bias. The investigator will ensure that all assisting study
personnel will be adequately qualified and informed about
the study protocol, any amendments, study medication
and study related responsibilities and functions. The in-
vestigator will maintain a study staff authorization log.
Each center will provide a stopwatch with minutes and
seconds to measure awaking times. The modified Aldrete
Score and PQRS form are enclosed in the Additional file 2
and 3 of the study protocol. After an initial pilot study of
133 patients, the PQRS tool was revised to its current
form, and a validation study of 701 participants was con-
ducted [9]. The VAS and VRS scales are valid, reliable and
appropriate for use in clinical practice [10]. Once a patient
is enrolled or randomized, the study site will make every
reasonable effort to follow the patient for the entire study
period until completion of phase G.
Premature treatment termination
The study will be terminated prematurely (dropout) for an
individual subject if the following occurs: serious intraop-
erative anesthesia complication, with required postopera-
tive transfer to intensive care unit for anesthesiological
reasons. The time point and specific reason for premature
treatment termination of each subject have to be docu-
mented. The investigator shall determine a fundamental
reason for premature treatment termination of each sub-
ject. All relevant safety data until subject’s treatment ter-
mination will be collected and reported. The study will be
terminated in the event the risk-benefit-ratio alters in such
a way, that premature treatment termination is indicated
to protect a subject’s health.
Premature study termination
Participants may withdraw from the study for any reason
at any time. As the follow-up period in this study is only
one day, we do not expect many withdrawals. Thesewithdrawals could only imply missing data for the PQRS
testing at T40 and on 1st POD.Data management
Standardization procedures will be implemented to en-
sure accurate, consistent, complete and reliable data,
including methods to ensure standardization among
sites (for example, training, newsletters, investigator
meetings, monitoring, centralized evaluations, and val-
idation methods). The monitors will be trained during
a kick-off meeting. Preparatory training to prepare the
investigators and to standardize performance will be
held during an investigators’ meeting before study start.
This study will be monitored regularly by a qualified moni-
tor from the sponsor Clinical Trial Center Aachen (CTC-
A) according to the good clinical practice (GCP) guidelines
and the respective SOPs (see Section Monitoring).
All data collected from a subject during the course of
this clinical study have to be entered and/or filed in the
respective subject file (CRF, case report forms). These
data will be considered as source data. The subject file
must contain a detailed statement on the informed con-
sent procedure. The subject’s participation in this study
must be appropriately documented in the subject file
with study number, subject number, date of subject in-
formation and informed consent, date of each visit, and
date of a potential telephone contact. If a study site is
using an electronic system for documenting source data,
a member of the site staff must print out the source data
after each visit. The paper printouts must be overlap-
ping, if possible (for example, must contain at least the
last row of data from the subject’s previous visit). Other-
wise, the thoroughness of source data must be ensured
by other suitable means. The printout must be signed
and dated by a member of the site staff who can confirm
the accuracy and completeness of data in the paper
printout. Additionally, the monitor shall sign and date
the verified paper printout. The paper printout shall be
stored in the investigator site file (ISF). If the source data
information is entered retrospectively, it must be done
directly on the paper printout and must be initialed and
dated. The same applies to any corrections of initial
data. Paper printouts are not required if the site is using
a validated computer system, including audit trail, with
separate access for the monitor (for example, monitor
has solely access to data of the study subjects). If correc-
tions are necessary, the subject shall be instructed to
draw a single line through the error, leaving the incor-
rect entry legible. The subject should date the correc-
tion, but not initial it. The investigator shall not falsify
the documents. The sponsor’s data management func-
tion will be responsible for data processing in accord-
ance with the sponsor’s data management procedures.
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procedures have been completed.
All source data related to study data should be kept in
locked cabinets. Access to the study data will be re-
stricted. Investigators will enter the information required
by protocol into an electronic data collection system via
internet (eCRF). The study data manager will develop
the eCRF. Detailed information on the eCRF completion
will be provided during the site initiation visits. An eCRF
completion manual will be provided to each site. An e-
learning tool will train all persons who enter data into
the eCRF. After the successful completion of the train-
ing, all participants will receive a training certificate. The
access to the e-learning tool and to the eCRF will be
password-controlled. Plausibility checks (including valid
values, range checks, and consistency checks) will be
performed according to a data validation plan to ensure
correctness and completeness of these data. Inconsisten-
cies will be queried via the electronic data collection
system; answers to queries or changes of the data will
directly be documented in the system. The database
will be closed after all data are entered and all queries
are solved. By signing the CRF (eCRF/eSignature), the
investigator will confirm that all investigations have
been completed and conducted in compliance with the
clinical study protocol, and that reliable and complete
data have been entered into the eCRF. The investigator
will keep the subject files and original data as long as
possible and according to the local procedure, but at
least for 10 years, as specified in the International
Conference on Harmonisation, (ICH)-GCP Guideline.
The investigator/institution should take measures to
prevent accidental or premature destruction of these
documents.Statistical methods
All efficacy, safety and economical results will be pre-
sented on the Intention to Treat (ITT) data set, which will
be composed of all randomized patients. In case it appears
necessary, we will define a secondary Per Protocol (PP)
data set prior to the database lock. The PP would be a
subset of the ITT data set, composed of all randomized
patients who have no major protocol deviations through-
out their entire study period. This PP data set would be
used for the secondary supportive analysis of the primary
efficacy criterion and serve as a check of its robustness.
Parametric data will be analyzed with ANOVA and
nonparametric data with the two-tailed Fisher’s exact
test if incidence <5 or the Chi-square test with inci-
dence >5. The inference for the noninferiority will be
based on the upper confidence bound. A fully specified
Statistical Analysis Plan will be made public before
unmasking results. Additional analyses are not planned.Data monitoring
The investigator is obliged to permit study specific mon-
itoring, auditing and inspections by the competent ethics
committee, to enable direct access to source data and
source documents and to support the respective person
to the best of his/her knowledge.
This study will be monitored regularly by a qualified
monitor from the sponsor CTC-A according to GCP
guidelines and the respective SOPs. Monitoring proce-
dures will include one or more visits designed to clarify
all prerequisites before the study commences. Interim
monitoring visits will take place on a regular basis accord-
ing to a mutually agreed upon schedule. During these
visits, the monitor will check for complete entries in the
eCRF/CRF: for compliance with the clinical study protocol,
ICH-GCP principles, the Declaration of Helsinki, regula-
tory authority requirements, for the integrity of the source
data with the eCRF/CRF entries, and for subject eligibility.
Monitoring will also be used to detect any misconduct or
fraud. In addition, the monitor will check whether all ad-
verse events (AEs) and serious adverse events (SAEs) have
been reported appropriately within the required time
periods. The investigator and all staff will be expected
to cooperate with the monitor by providing any missing
information whenever possible. The investigator must
be available to answer questions arising during regular
monitoring visits. Additionally, the investigator is re-
quired to:
 Have all data recorded in the eCRF and subject files
properly, prior to each monitoring visit
 Have the source documentation available at the
monitoring visits
All subjects who give their informed consent, including
those screened but not enrolled into the study, will be
listed on the subject screening/enrollment log. Further de-
tails of monitoring activities will be set forth in the moni-
toring manual.
Interim analyses are not planned. Failure of this study
is unlikely, as all study treatments are performed during
clinical routine and the required patient number will
probably be achieved during the clinical routine of the
participating sites. If unexpected SAEs occur in connec-
tion with the study treatment, the coordinating principal
investigator and the sponsor will discuss the termination
of the trial.
Harms
Safety assessments will consist of monitoring and record-
ing all AEs and SAEs by regularly monitoring of the mea-
sured vital parameters and physical examinations. The
investigator will be provided with AE and SAE reporting
forms by CTC-A, receive training for AE/SAE definition,
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tion and reporting will be monitored on site.
Definition of AEs:
An AE is defined in the ICH Guideline for GCP as
“any untoward medical occurrence, including an exacer-
bation of a pre-existing condition, in a patient or clinical
investigation subject administered a pharmaceutical
product and that does not necessarily have a causal rela-
tionship with this treatment.” (ICH E6:1.2) Each AE has
to be reported on an Adverse Event Case Report Form.
As far as possible, each AE has to be described accord-
ing to the following:
1. Its duration (start and end dates)
2. Its severity grade (mild, moderate, or severe)
3. Its relationship to the study drug (suspected/not
suspected)
4. Treatment required and action taken with trial drug
5. Outcome
6. Seriousness
Examples of the severity grade, relationship to study
treatment and actions taken, as presented in the case re-
port form, are provided below. The severity grade of an
AE provides a qualitative assessment of the extent or in-
tensity of an AE, as determined by the investigator or as
reported by the subject. The severity grade does not re-
flect the clinical seriousness of the event, only the degree
or extent of the affliction or occurrence (for example, se-
vere nausea, mild seizure), and does not reflect the rela-
tionship to study drug.
Severity grade for an AE:
The intensity of the AE should be judged based on the
following:
1 = Mild Awareness of sign(s) or symptom(s) that is/are
easily tolerated
2 = Moderate Enough discomfort to cause interference
with usual activity
3 = Severe Incapacitating or causing inability to work or
to perform usual activities
Causal relationship of AE:
Medical judgment should determine the relationship,
considering all relevant factors, including the pattern of
reaction, temporal relationship, de-challenge or re-challenge,
confounding factors such as concomitant medication,
concomitant diseases and relevant history. An assess-
ment of causal relationship must be recorded for each
AE.
Causality will be reported as either “Yes” or “No”:
Yes: There is a reasonable causal relationship between
the investigational product administered and the AE.
No: There is no reasonable causal relationship between
the investigational product administered and the AE.
Definition of SAEs:A serious adverse event (SAE) is defined as an adverse
event as follows:
 Results in death (fatal)
 Is immediately life-threatening
 Results in persistent or significant disability/incapacity;
 Requires or prolongs patient hospitalization;
 Is a congenital anomaly/ birth defect;
or
 Based upon appropriate medical judgment, may
jeopardize the patient and may require medical or
surgical intervention to prevent one of the afore-
mentioned outcomes (for example, intensive treatment
in an emergency room without hospitalization)
A hospitalization meeting the regulatory definition for
“serious” is any inpatient hospital admission that includes
a minimum of an overnight stay in a health care facility.
Any AE that does not meet one of the definitions of
serious (for example, emergency room visit, outpatient
surgery, or urgent investigation) may be considered by
the investigator to meet the “other significant medical
hazard” criterion for classification as a SAE. An event does
not need to be reported as an SAE if it represents only a
relapse or an expected change or progression of the condi-
tion that was the cause of treatment without any other
symptoms and signs than those present before treatment.
This type of event needs only to be reported as an AE.
Reporting Procedures of SAEs:
All SAEs have to be reported by the principal investiga-
tor to the sponsor (CTC-A) within 24 hours of discovery
or notification of the event. The sponsor will collect all
SAE reports and write the annual safety report.
Auditing
Audits will be performed according to the corresponding
audit program, including the possibility that a member
of the sponsor’s quality assurance function may arrange
to visit the investigator in order to audit the performance
of the study at the study site, as well as all study documents
originating there. Auditors conduct their work independ-
ently of the clinical study and its performance. Contract
auditors may also perform audits. In that case, the spon-
sor’s quality assurance function will agree with the contract
auditor regarding the timing and extent of the audit(s). In
case of audits at the investigational site, the monitor will
usually accompany the auditor(s).
Ethics and dissemination
Research ethics approval
The study will be performed in accordance with the eth-
ical principles that have their origin in the Declaration
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Helsinki, the German Medicines Act (Deutsches Arznei-
mittelgesetz (AMG)), as well as the GCP-Guideline, the
study was presented to the leading Ethics Committee of
the University of RWTH Aachen, 52074 Aachen, which
is related to the coordinating investigator. The local
Ethics Committees of the other three centers (1. Halle:
Ethik-Kommission des Landes Sachsen-Anhalt, 06846
Dessau-Roßlau; 2. Reutlingen: Ethik-Kommission bei der
Landesärztekammer Baden-Württemberg, 70597 Stuttgart;
3. Ulm: Ethics Committee of the University of Ulm,
89081 Ulm) had only advisory function. The ethical ap-
proval with the reference number EK 314/14 was received
on 15 January 2015. Any change in the study protocol
and/or informed consent form will be presented to the
Ethics Committees. These would have to be approved by
the leading Ethics Committee before implementation
(except for changes in logistics and administration or
when necessary to eliminate immediate hazards). Add-
itionally, the sponsor had already requested approval
from the respective competent authority (Federal Insti-
tute for Drugs and Medical Devices (BfArM), Germany).
This request was approved on 15.12.2014. The sponsor
will provide copies of the approval documentation to the
principal investigator of each center for his/her files. Any
change in the study protocol will have to be approved by
the competent Authority. They have to be approved by
the competent authority before implementation (except
for changes in logistics and administration or to eliminate
immediate hazards).
The notification of the clinical trial according to § 67
German Medical Act to the local supervising authority
was performed by the sponsor according to the SOP and
with the consent of the principal investigator. The same
procedure will account for any amendments after the
end of the study as well. The sponsor will provide a copy
of the notification to the principal investigator for his files.
Protocol amendments
The authorization of the relevant competent authority
and approval of the ethics committee for any amendments
that may become necessary during the study will be ap-
plied by the sponsor, CTC-A, according to the SOPs.
Reportable amendments are changes, which may affect
the following:
 Safety of subjects
 Integrity and credibility of data
 Protocol amendment
 Changes in risk evaluation of drugs consisting/
including genetically modified organisms
Every amendment of the protocol has to be signed by the
coordinating investigator, the sponsor and the biostatistician.Consent
According to AMG and GCP-Guidelines, informed con-
sent has to be obtained from subjects prior to participa-
tion in the trial. The subjects will voluntarily confirm
their willingness to participate in the trial, after having
been informed by a physician verbally and in writing of
all aspects of the trial that are relevant to the subject’s
decision to participate. Patients will be informed about
the requirements concerning data protection and have
to agree to direct access to their individual data. The
subjects will sign an informed consent form for study
participation as well as the disclosure of individual data.
The informed consent form has to be signed and dated
by the subject and one of the sub-investigators. Before
written informed consent is obtained, the investigator
must provide the subject ample time and opportunity to
inquire about details of the trial and to decide whether
or not to participate. All questions regarding the trial
have to be answered to the satisfaction of the subject.
The subject information and informed consent form will
be prepared and informed consent will be obtained from
the subject according to sponsors’ SOPs. The partici-
pants will receive copies of the informed consent forms.
The participant will be informed by a physician in a
timely manner if new information becomes available that
may be relevant to the subject’s willingness to continue
participation in the trial. The communication of this in-
formation will be documented. The subject will receive a
copy of any amendments to the written information and
a copy of the signed and dated consent form updates.
Subjects will be informed that they are free to withdraw
from the study at any time at their own discretion with-
out necessarily giving reasons. The participation in the
clinical trial has to be documented on the patient’s
health records.
Confidentiality
Patients will be informed about data protection and that
data will be pseudonymized and handed over to a third
party after being anonymized. Access to encoded data or
source documents will only be given to authorized bod-
ies or persons (sponsor, authorized staff, auditors, com-
petent authorities or ethics commission) for validation
of data. Also in case of publication, confidentiality of the
collected data will be guaranteed. A unique randomization
number will identify all subjects. Each investigator will
maintain a subject identification list according to the
Sponsor’s SOP, which enables the identification of the sub-
jects by withholding information about the subject’s per-
sonal data and randomization number. This list will be
stored safely (limited access) in the investigator’s site file.
The subject’s informed consent, which bears subject’s
printed name and signature, will be filed separately in
another investigators’ file. Monitors, auditors or the
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sonal data but copying of the identification list or an in-
formed consent is without exception prohibited.
Where required, personal data, and health data in par-
ticular, may be handled as follows:
 Held for inspection by the competent ethics
committee for monitoring the orderly performance
of the study,
 Passed on to the investigators or an authorized party
for analysis under a pseudonym.
Access to data
Following termination of the study, all principle investiga-
tors, the sponsor and Baxter will have access to the
cleaned data sets.
Ancillary and post-trial care
No specific post-study arrangements are made and no
specific post-study care will be performed after this study.
All patients will return to their standard medical care sub-
sequently, as needed. This also applies to subjects who
withdraw their consent during the course of the study.
Dissemination policy
The study results will be published in appropriate inter-
national scientific journals, and publishing details will be
specified in the clinical study agreement. The final re-
port will follow the main CONSORT guideline as well as
its extension to non-inferiority trials.
The study is already registered at the registries EudraCT
and ClinicalTrials.gov and the principal investigator will
disclose the study results there, according to national/
international protocol.
Discussion
We have identified very few RCTs comparing desflurane
to other commonly used anesthetics (sevoflurane, propofol
and isoflurane) in patients undergoing general anesthesia
with LMA [4]. There were no significant differences re-
garding the frequency of upper airway complications dur-
ing the anesthesia or at emergence, though the emergence
times in the desflurane group were faster. Due to the small
sample sizes of these trials and enormous trial inconsisten-
cies [5], there remains a lack of evidence confirming the re-
sults of our previous meta-analysis [4]. Furthermore there
was a high risk of performance bias in all trials and only
two have precisely described the randomization process
[11, 12]. In the present large multicenter RCT, all patients
will receive the same dosage of additional agents (for ex-
ample, lidocaine at induction, the same kind of opioids and
no muscle relaxants) in regard on their possible impact on
the outcome variables. It is not feasible to blind the attend-
ing anesthetist to the intervention group. Therefore, weaim to minimize the performance bias by providing a strict
but in clinical routine feasible study protocol for the inter-
vention performance. A second, blinded investigator will
assess the pre- and postoperative outcome data to reduce
the detection bias to a minimum.
Furthermore, the previous trials analyzed in our meta-
analysis [4] mainly included ASA I-II patients. However,
ASA III patients would also benefit from the LMA, es-
pecially in regard to significantly better hemodynamic
stability at anesthesia induction and during the emergence.
The inclusion of ASA III patients in our RCT will allow us
to extend our findings to this patient group. Finally, the re-
covery on the 1st POD was only assessed in four reviewed
trials with different assessment methods [11, 13–15].
We have chosen the PQRS test, as it was also validated
for the assessment of later recovery in patients remaining
in the hospital as well as via telephone questionnaire once
the patient was discharged home [9]. We will perform the
PQRS testing on the 1st POD in all patients, either on the
ward or via telephone. Another significant advantage of
our RCT is that the recruitment and conduction process
can work within the usual clinical routine.
Risk benefit assessment
All drugs used in this trial are anesthetics that have been
used in the daily clinical routine for many years. Harms
are not expected for any study group. If desflurane enables
significant faster emergence from anesthesia, it would have
a positive impact on the patient recovery from anesthesia
with probably faster discharge times. This would certainly
enhance patient comfort and improve cost effectiveness.
Trial status
Patient recruitment started at the end of February 2015.
The predicted study recruiting end-date is September
2015.
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Additional file 1: Participant timeline. Schedule of enrollment,
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